Bristol-Myers Squibb vs Pfizer BMY vs PFE
Bristol-Myers Squibb and Pfizer on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Return on equity: Bristol-Myers Squibb 41.6%, Pfizer 5.1%.
- Trailing P/E: Pfizer 39.3×, Bristol-Myers Squibb 13.6×.
- Net margin: Bristol-Myers Squibb 18.9%, Pfizer 6.8%.
- Debt / equity: Bristol-Myers Squibb 1.9×, Pfizer 0.7×.
Price return
2025-10-26 → 2026-10-26
BMY+40.6%
PFE+20.3%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$125.85B
$169.79B
Enterprise value
$160.25B
$232.01B
Employees
32,500
75,000
Revenue per employee (TTM)
$1.5M
$849K
Our models
nightlythe valuation on each stock's pagePrice vs model
37% undervalued vs model
39% undervalued vs model
Model range
$50.26–231
$24.96–113
Models in the headline
1
1
FCF growth priced in, at a 10% return
1.1%
13.3%
Every model, its assumptions and its range: BMY valuation · PFE valuation. The growth priced in, at any return: BMY reverse DCF · PFE reverse DCF.
Trading
close 2026-10-26Last close
$61.61
$29.79
52-week high
$68.09
$30.42
52-week low
$42.60
$23.67
Price vs 52-week high
−9.5%
−2.1%
Price vs 52-week low
+44.6%
+25.9%
Average daily volume / shares
0.6%
0.7%
Beta
0.23
0.28
Returns
to 2026-10-261 month
−2.0%
+3.9%
3 months
−0.8%
+21.4%
6 months
+4.9%
+10.3%
Year to date
+14.2%
+19.6%
1 year
+40.6%
+20.3%
1 year, dividends added
+46.3%
+27.3%
2 years
+18.7%
+4.7%
Valuation
price × TTM to Jun 2026P/E (TTM)
13.6×
39.3×
P/E on consensus EPS (next FY)
9.7×
10.1×
Price / sales
2.6×
2.7×
EV / sales
3.3×
3.6×
EV / EBITDA
9.5×
17.2×
Price / book
5.6×
2.0×
Price / free cash flow (FY)
9.8×
18.7×
Free-cash-flow yield (FY)
10.2%
5.3%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+3.5%
−0.5%
Revenue, 3-year CAGR
1.4%
−14.6%
Revenue, 5-year CAGR
2.5%
8.5%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+83.2%
+117.3%
EPS, 3-year CAGR
5.4%
−37.1%
Free cash flow, 3-year CAGR
2.4%
−29.6%
Diluted shares, 3-year change
−4.9%
−0.8%
Profitability
TTM to Jun 2026Gross margin (FY)†
71.1%
70.3%
Operating margin
28.1%
25.1%
EBITDA margin
34.2%
21.2%
Net margin
18.9%
6.8%
Free-cash-flow margin (FY)
26.7%
14.5%
Return on equity
41.6%
5.1%
Return on assets
10.6%
2.2%
Asset turnover
0.56
0.32
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$8.72B
$976.0M
Total debt
$43.12B
$63.19B
Net debt
$34.40B
$62.22B
Debt / equity
1.9×
0.7×
Net debt / EBITDA (TTM)
2.0×
4.6×
Interest coverage (FY)
7.3×
5.8×
Current ratio (FY)
1.26
1.16
Dividends
trailing 12 monthsDividend yield
4.1%
5.8%
Dividends per share
$2.52
$1.72
Payout ratio (of TTM EPS)
55.5%
227.2%
Dividend per share, 5-year CAGR
5.2%
2.1%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
8
11
Insider open-market buys (Form 4)
$0
$3.0M
Insider sales (Form 4)
$437K
$83K
Analyst upgrades
1
0
Analyst downgrades
1
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$49.19B
$63.70B
EBITDA
$16.82B
$13.49B
Operating income
$13.84B
$15.98B
Net income
$9.28B
$4.33B
EPS (diluted)
$4.54
$0.76
Operating cash flow
$14.16B
$11.71B
Capital expenditure
−$1.31B
−$2.63B
Free cash flow
$12.85B
$9.08B
Dividends paid
$5.04B
$9.77B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.